Cargando…

Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study

BACKGROUND/AIMS: Large-scale population studies measuring rates and dynamics of cognitive decline in multiple sclerosis (MS) are lacking. In the current cross-sectional study we evaluated the patterns of cognitive impairment in MS patients with disease duration of up to 30 years. METHODS: 1,500 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Achiron, Anat, Chapman, Joab, Magalashvili, David, Dolev, Mark, Lavie, Mor, Bercovich, Eran, Polliack, Michael, Doniger, Glen M., Stern, Yael, Khilkevich, Olga, Menascu, Shay, Hararai, Gil, Gurevich, Micharel, Barak, Yoram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731335/
https://www.ncbi.nlm.nih.gov/pubmed/23936485
http://dx.doi.org/10.1371/journal.pone.0071058
_version_ 1782279150574239744
author Achiron, Anat
Chapman, Joab
Magalashvili, David
Dolev, Mark
Lavie, Mor
Bercovich, Eran
Polliack, Michael
Doniger, Glen M.
Stern, Yael
Khilkevich, Olga
Menascu, Shay
Hararai, Gil
Gurevich, Micharel
Barak, Yoram
author_facet Achiron, Anat
Chapman, Joab
Magalashvili, David
Dolev, Mark
Lavie, Mor
Bercovich, Eran
Polliack, Michael
Doniger, Glen M.
Stern, Yael
Khilkevich, Olga
Menascu, Shay
Hararai, Gil
Gurevich, Micharel
Barak, Yoram
author_sort Achiron, Anat
collection PubMed
description BACKGROUND/AIMS: Large-scale population studies measuring rates and dynamics of cognitive decline in multiple sclerosis (MS) are lacking. In the current cross-sectional study we evaluated the patterns of cognitive impairment in MS patients with disease duration of up to 30 years. METHODS: 1,500 patients with MS were assessed by a computerized cognitive battery measuring verbal and non-verbal memory, executive function, visual spatial perception, verbal function, attention, information processing speed and motor skills. Cognitive impairment was defined as below one standard deviation (SD) and severe cognitive impairment as below 2SD for age and education matched healthy population norms. RESULTS: Cognitive performance in our cohort was poorer than healthy population norms. The most frequently impaired domains were information processing speed and executive function. MS patients with secondary-progressive disease course performed poorly compared with clinically isolated syndrome, relapsing-remitting and primary progressive MS patients. By the fifth year from disease onset, 20.9% of patients performed below the 1SD cutoff for impairment, p = 0.005, and 6.0% performed below the 2SD cutoff for severe cognitive impairment, p = 0.002. By 10 years from onset 29.3% and 9.0% of patients performed below the 1SD and 2SD cutoffs, respectively, p = 0.0001. Regression modeling suggested that cognitive impairment may precede MS onset by 1.2 years. CONCLUSIONS: The rates of cognitive impairment in this large sample of MS patients were lower than previously reported and severe cognitive impairment was evident only in a relatively small group of patients. Cognitive impairment differed significantly from expected normal distribution only at five years from onset, suggesting the existence of a therapeutic window during which patients may benefit from interventions to maintain cognitive health.
format Online
Article
Text
id pubmed-3731335
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37313352013-08-09 Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study Achiron, Anat Chapman, Joab Magalashvili, David Dolev, Mark Lavie, Mor Bercovich, Eran Polliack, Michael Doniger, Glen M. Stern, Yael Khilkevich, Olga Menascu, Shay Hararai, Gil Gurevich, Micharel Barak, Yoram PLoS One Research Article BACKGROUND/AIMS: Large-scale population studies measuring rates and dynamics of cognitive decline in multiple sclerosis (MS) are lacking. In the current cross-sectional study we evaluated the patterns of cognitive impairment in MS patients with disease duration of up to 30 years. METHODS: 1,500 patients with MS were assessed by a computerized cognitive battery measuring verbal and non-verbal memory, executive function, visual spatial perception, verbal function, attention, information processing speed and motor skills. Cognitive impairment was defined as below one standard deviation (SD) and severe cognitive impairment as below 2SD for age and education matched healthy population norms. RESULTS: Cognitive performance in our cohort was poorer than healthy population norms. The most frequently impaired domains were information processing speed and executive function. MS patients with secondary-progressive disease course performed poorly compared with clinically isolated syndrome, relapsing-remitting and primary progressive MS patients. By the fifth year from disease onset, 20.9% of patients performed below the 1SD cutoff for impairment, p = 0.005, and 6.0% performed below the 2SD cutoff for severe cognitive impairment, p = 0.002. By 10 years from onset 29.3% and 9.0% of patients performed below the 1SD and 2SD cutoffs, respectively, p = 0.0001. Regression modeling suggested that cognitive impairment may precede MS onset by 1.2 years. CONCLUSIONS: The rates of cognitive impairment in this large sample of MS patients were lower than previously reported and severe cognitive impairment was evident only in a relatively small group of patients. Cognitive impairment differed significantly from expected normal distribution only at five years from onset, suggesting the existence of a therapeutic window during which patients may benefit from interventions to maintain cognitive health. Public Library of Science 2013-08-01 /pmc/articles/PMC3731335/ /pubmed/23936485 http://dx.doi.org/10.1371/journal.pone.0071058 Text en © 2013 Achiron et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Achiron, Anat
Chapman, Joab
Magalashvili, David
Dolev, Mark
Lavie, Mor
Bercovich, Eran
Polliack, Michael
Doniger, Glen M.
Stern, Yael
Khilkevich, Olga
Menascu, Shay
Hararai, Gil
Gurevich, Micharel
Barak, Yoram
Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study
title Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study
title_full Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study
title_fullStr Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study
title_full_unstemmed Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study
title_short Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study
title_sort modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731335/
https://www.ncbi.nlm.nih.gov/pubmed/23936485
http://dx.doi.org/10.1371/journal.pone.0071058
work_keys_str_mv AT achironanat modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT chapmanjoab modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT magalashvilidavid modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT dolevmark modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT laviemor modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT bercovicheran modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT polliackmichael modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT donigerglenm modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT sternyael modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT khilkevicholga modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT menascushay modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT hararaigil modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT gurevichmicharel modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy
AT barakyoram modelingofcognitiveimpairmentbydiseasedurationinmultiplesclerosisacrosssectionalstudy